RESTEM is a leading clinical-stage biotechnology company focused on developing off-the-shelf, next-generation cell therapies designed to modulate the immune system. Leveraging our proprietary products, robust clinical development expertise, and cutting-edge-manufacturing capabilities, we advance potentially groundbreaking, wholly owned programs, Restem-L, an umbilical cord lining stem cells (ULSCs) for auto-immune diseases, Restem-X, a secretome-based product for orthopedic conditions, and activated natural killer cell (aNK) therapeutics targeting senescence and age-associated disorders. Our therapies are intended to treat a broad range of disabling diseases and are designed to improve patient outcomes, as well as overall health and wellness.